JSPR Jasper Therapeutics, Inc.
$0.52▲ +2.67%
Healthcare
Other
Volume 1.32M
Avg Volume (10D) 358.4K
Key Metrics & Fundamentals
Market Cap
$17.27M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.32 - 2.52
% vs 50 MA
-15.46%
% vs 200 MA
-40.15%
RSI-14
43.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.80
Free Cash Flow
-$6.92M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$13.17M
COGS
–
Operating Exp
$9.21M
Operating Income
-$9.21M
EBIT
-$9.21M
Pretax Income
-$2.76M
Net Income
-$2.76M
EPS (Diluted)
-0.10
Price & Volume History
Loading chart…
Recent News
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
GlobeNewswire · Oct 15, 2026 8:00 AM ET
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
GlobeNewswire · Oct 7, 2026 8:00 AM ET
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
GlobeNewswire · Sep 15, 2026 4:05 PM ET
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 9, 2026 8:00 AM ET
Jasper Therapeutics beats Q2 expectations but shares fall after results
InvestorsHub · Aug 17, 2026 8:30 AM ET
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 14, 2026 11:00 AM ET
Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target
MT Newswires · Aug 12, 2026 6:52 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See JSPR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.